137 271

Cited 15 times in

A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.

Authors
Lee, K; Yang, H; Lim, H; Lew, HM
Citation
Retina (Philadelphia, Pa.), 29(10):1409-1417, 2009
Journal Title
Retina (Philadelphia, Pa.)
ISSN
0275-004X1539-2864
Abstract
PURPOSE: To evaluate the changes in blood pressure and intraocular pressure (IOP) in patients with and without hypertension after intravitreal bevacizumab (Avastin) injection. METHODS: This study examined 135 (74 nonhypertensive vs. 61 hypertensive) consecutive patients treated with an intravitreal injection of 1.25 mg bevacizumab for retinal vascular diseases prospectively over a 6-month period. All the hypertensive patients were on medication, and only patients with controlled hypertension after consultation with cardiology specialists were included. Intraocular pressure and blood pressure were measured before and 30 minutes, 1 day, 1 week, 3 weeks, and then every month after the bevacizumab injection. RESULTS: The mean baseline systolic and diastolic pressures were significantly higher in the hypertensive group (systolic P = 0.001, diastolic P = 0.023). None of the systolic and diastolic values after injection differed significantly from the baseline values in the hypertensive group. By contrast, the 30-minute systolic values were significantly higher than baseline (P < 0.05), and the 1-day diastolic values were lower than before injection in the nonhypertensive group (P < 0.05). The mean baseline IOP of the nonhypertensive and hypertensive groups was similar (P = 0.08). The mean IOP 30 minutes after injection was significantly higher than the baseline mean IOP (P < 0.05), and the mean IOPs at 1 day and 1 week were significantly lower than before injection in both groups (P < 0.05). CONCLUSION: Intravitreal bevacizumab injection is safe in terms of blood pressure and IOP in both hypertensive and nonhypertensive patients after 6 months of follow-up.
MeSH terms
AdultAgedAged, 80 and overAngiogenesis Inhibitors/administration & dosage*Antibodies, Monoclonal/administration & dosage*Antihypertensive Agents/administration & dosageBlood Pressure/drug effects*Blood Pressure/physiologyChoroidal Neovascularization/drug therapy*FemaleHumansHypertension/complications*Hypertension/drug therapyHypertension/physiopathologyInjectionsIntraocular Pressure/drug effects*Intraocular Pressure/physiologyMaleMiddle AgedProspective StudiesRetinal Diseases/drug therapy*Vascular Endothelial Growth Factor A/antagonists & inhibitorsVitreous Body
DOI
10.1097/IAE.0b013e3181b21056
PMID
19816242
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
AJOU Authors
양홍석유호민
Full Text Link
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse